Innorna

Founded in 2019, Innorna is committed to developing state-of-the-art LNP delivery systems and RNA therapies to address unmet medical needs. Its proprietary Diversity-Oriented Lipid Library—with over ionizable lipids—enables breakthroughs in innovative RNA medicines, including mRNA vaccines and therapeutics. Leveraging its innovative mRNA-LNP platform, Innorna has built a robust pipeline targeting infectious diseases, rare diseases, metabolic disorders, and cancer immunotherapy. Beyond its internal R&D efforts, the company collaborates with global-leading biotechnology partners to expand the reach of its transformative technology. Recognized by investors and industry peers, Innorna has received numerous accolades including Forbes China Industry Leaders, MIT Technology Review’s 50 Smartest Companies, and Fortune China Impact Startups. Learn more at HONG KONG: Rm 12 W Science and Technology West Avenue, Phase 3, HKSTP, Shatin, HKSAR